Pembrolizumab Prolonged PFS vs Brentuximab in Hodgkin Lymphoma

Pembrolizumab significantly improved progression-free survival vs brentuximab in a recent phase 3 trial with patients with relapsed or refractory classical Hodgkin lymphoma. Medscape Medical News